FDA Inspection 1209584 — OCUPHIRE PHARMA INC
The FDA completed an inspection of OCUPHIRE PHARMA INC on June 29, 2023 in Farmington Hills, MI. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 29, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Farmington Hills, MI (United States)
Additional Details
Sponsor, Contract Research Organization